Health Canada grants full approval to GSK’s Jemperli as monotherapy

GSK announced that Health Canada granted full approval for Jemperli as a monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen. “We remain committed to exploring the full potential of Jemperli as the foundation of our immuno-oncology portfolio, aiming to meet the needs of patients in various stages of endometrial cancer and other types of solid tumours,” said Marni Freeman, Country Medical Director at GSK Canada. “This approval in Canada reaffirms our belief in the value of Jemperli as a treatment choice for patients who are living with dMMR/MSI-H recurrent or advanced endometrial cancer.” This approval is based on additional data collected from the A1 expansion cohort of the ongoing GARNET trial, a phase I, multicentre, open-label, single-arm study of Jemperli monotherapy in patients with advanced or recurrent solid tumours. Confirmed objective response rate was 45.5%, and the median duration of response was not reached, with a median follow-up for duration of response of 27.6 months.